Product Description
Anti-OX40 tetravalent agonistic humanized monoclonal antibody. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05788107?term=HLX-51&draw=2&rank=1)
Mechanisms of Action: OX40 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Henlius Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HLX51-FIH101 | P1 |
Not yet recruiting |
Lymphoma |
2025-05-01 |
29% |
2025-06-03 |
Primary Endpoints|Treatments |
| CTR20231940 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment |
Recent News Events
Date |
Type |
Title |
|---|